Mercado mundial de diagnóstico de enfermedades infecciosas en el punto de atención: tendencias de la industria y pronóstico hasta 2031

Análisis y tamaño del mercado de diagnóstico de enfermedades infecciosas en el punto de atención

El mercado de diagnóstico de enfermedades infecciosas en el punto de atención está experimentando un crecimiento significativo impulsado por la creciente demanda de soluciones de diagnóstico rápidas y precisas en entornos de atención médica en todo el mundo. Estos diagnósticos son cruciales para permitir la detección y el manejo oportunos de la enfermedad, en particular para las enfermedades infecciosas donde la intervención rápida es fundamental para prevenir la transmisión y mejorar los resultados del paciente. El mercado está respaldado por los avances en las tecnologías de diagnóstico, incluidos los diagnósticos moleculares, los inmunoensayos y las pruebas rápidas de antígenos, que permiten realizar pruebas rápidas y eficientes en el punto de atención del paciente o cerca de él. Las soluciones POC IDD ofrecen a los proveedores de atención médica la capacidad de diagnosticar rápidamente las infecciones, iniciar los tratamientos adecuados y monitorear las respuestas de los pacientes en tiempo real, lo que reduce la carga en los laboratorios centralizados y mejora la eficiencia de la atención médica.

El tamaño del mercado global de diagnóstico de enfermedades infecciosas en el punto de atención se valoró en USD 2.20 mil millones en 2023 y se proyecta que alcance los USD 6.42 mil millones para 2031, con una CAGR durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como valor de mercado, tasa de crecimiento, segmentación, cobertura geográfica y actores principales, los informes de mercado seleccionados por Data Bridge Market Research también incluyen análisis de expertos en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado       

Market Definition

Point of care infectious disease diagnostics refers to diagnostic tests performed at or near the patient's location, typically within a healthcare setting such as a clinic, doctor's office, or field setting, rather than in a centralized laboratory. These tests are designed to provide rapid and accurate results, enabling healthcare providers to make immediate treatment decisions. POC IDD technologies encompass a variety of methods, including molecular diagnostics, immunoassays, and rapid diagnostic tests (RDTs).                          

Point of Care Infectious Disease Diagnostics Market Dynamics

Drivers

• Demand for Rapid Diagnosis

The increasing demand for rapid diagnostic solutions in healthcare settings is driven by the urgent need to detect infectious diseases swiftly at the point of care. These solutions enable healthcare providers to promptly initiate appropriate treatments, thereby improving patient outcomes and reducing transmission risks within communities. Rapid diagnostic tests (RDTs), molecular diagnostics, and antigen tests are pivotal in diagnosing infections such as influenza, tuberculosis and emerging outbreaks such as COVID-19. This demand is particularly critical in emergency departments, clinics, and remote areas where immediate diagnosis can significantly impact disease management and public health outcomes.

• Increasing Prevalence of Infectious Diseases

The global rise in infectious diseases, exacerbated by factors such as population growth, urbanization, and international travel, underscores the importance of adopting point-of-care diagnostics for infectious diseases. Infectious disease outbreaks, including pandemics like COVID-19, highlight the necessity for rapid and accurate diagnostic tools that can quickly identify pathogens and facilitate timely intervention strategies. POC IDD solutions play a crucial role in surveillance, early detection, and containment efforts, empowering healthcare systems to effectively manage disease spread and mitigate public health crises through targeted interventions and preventive measures.

Opportunities

• Development of Multiplex Assays

Advancements in multiplex assay technologies are transforming Point of Care Infectious Disease Diagnostic (POC IDD) devices. These assays allow simultaneous detection of multiple pathogens or biomarkers in a single test, boosting diagnostic efficiency and broadening the applications of POC IDD devices. By consolidating testing procedures and cutting turnaround times, multiplex assays help healthcare providers quickly make informed decisions, especially during complex clinical situations or outbreaks where identifying several pathogens swiftly is crucial. This innovation not only enhances diagnostic accuracy but also improves how healthcare resources are used and creates new market opportunities.  

• Integration with Digital Health Platforms  

Linking POC IDD devices with digital health platforms opens up new possibilities for healthcare delivery. By connecting diagnostic data with electronic health records (EHRs), telemedicine platforms, and real-time monitoring systems, healthcare providers can streamline workflows, enhance patient care, and enable remote consultations. This digital integration makes it easier to transmit diagnostic results, improving access to healthcare services, particularly in remote or underserved areas where traditional infrastructure may be lacking, creating new opportunities for the point of care infectious disease diagnostics market.

Restraints/Challenges

• Regulatory Challenges

Stringent regulatory requirements for the approval and commercialization of POC IDD devices present significant challenges for manufacturers and market entry. Compliance with diverse regulatory frameworks across different regions necessitates comprehensive testing, validation, and documentation, adding complexity and time to the product development lifecycle. Regulatory barriers can impede innovation and market access, particularly for novel technologies or devices seeking global deployment.  

• Accuracy and Reliability Concerns

Concerns regarding the accuracy and reliability of POC IDD devices compared to laboratory-based assays remain a critical consideration for healthcare providers and regulatory bodies. Variability in test performance under different environmental conditions, operator proficiency, and specimen quality can impact diagnostic accuracy and reliability, potentially influencing clinical decision-making.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In October 2023, QIAGEN achieved CE certification for its IVD kit and automated testing platform, NeuMoDx. This development significantly boosted the company’s revenue and market share
• In May 2023, Danaher Corporation introduced the Dxl 9000 Access Immunoassay Analyzer capable of processing up to 215 tests per hour. This launch expanded the company’s offerings in point-of-care diagnostics
• In May 2023, BD announced 510k clearance for its BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) imaging application, which incorporates AI software. This innovation reduces test result turnaround times by automating the labor-intensive process of identifying bacterial growth traditionally done using petri dishes

Point of Care Infectious Disease Diagnostics Market Scope

The market is segmented on the basis of product, technology, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Consumables
• Instruments
• Software and Services

Technology

• Lateral Flow
• Agglutination Assays
• Flow-Through
• Solid Phase

Application

• HIV
• Tropical Disease
• Liver Disease
• Inflammatory Disease
• Respiratory Disease
• Hospital Associated Infections
• Sexual Health Disorders

End User

• Hospitals
• Healthcare Centers
• Laboratories
• Independent Diagnostic Centers
• Home Care Settings

Point of Care Infectious Disease Diagnostics Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, product, technology, application, and end user as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to a significant rise in the adoption of testing instruments in hospitals to meet the growing demand for point-of-care diagnostics for various infectious diseases. The availability of robust healthcare and medical facilities, coupled with heightened awareness and the presence of skilled professionals, further consolidates its position as the dominant market.

Asia-Pacific is expected to witness significant growth during the forecast period due to ongoing investments in healthcare infrastructure and other medical advancements. This growth is characterized by expanding access to healthcare facilities, increased investment in medical technologies, and enhanced healthcare services. These developments contribute significantly to the region's emerging prominence in the healthcare sector.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Point of Care Infectious Disease Diagnostics Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Algunos de los principales actores que operan en el mercado son:

• Siemens Healthineers AG (Alemania)
• Trivitron Healthcare (India)
• F. Hoffmann-La Roche Ltd (Suiza)
• Abbott (Estados Unidos)
• Quest Diagnostics Incorporated (Estados Unidos)
• BD (Estados Unidos)
• Chembio Diagnostics Inc. (Estados Unidos)
• Trinity Biotech (Irlanda)
• Cardinal Health (Estados Unidos)
• Bio-Rad Laboratories Inc. (Estados Unidos)
• bioMérieux SA (Francia)
• Thermo Fisher Scientific Inc. (Estados Unidos)
• Corporación Quidel (Estados Unidos)
• OJ-Bio Limited (Reino Unido)

SKU-63670